NAD replenishment therapy for Parkinson’s disease

Parkinson’s disease (PD) is the most rapidly growing neurological disorder worldwide. There are currently more than 10 million people with PD and this number is expected to double by 2040. While the pharmaceutical market for PD is forecasted to reach $11 billion by 2029, all current treatments are purely symptomatic, making no impact on disease progression. Thus, patients continue to face a future of progressive disability, early institutionalization, and premature death. The complete lack of neuroprotective therapies is one of the greatest unmet needs and, at the same time, business opportunities in the treatment market of PD.? Our project aims to establish a neuroprotective, disease-modifying therapy for PD and to position this therapy for commercialization. We will achieve this by harnessing the neuroprotective potential of augmenting NAD metabolism in the human brain, something our group recently showed to be feasible using oral precursors, thus nominating NAD boosting as a potential neuroprotective therapy for PD. Importantly, we have secured extensive IP protecting our findings, which we will further develop in this project.? This verification project will enable us to make an essential leap forward in both the scientific and commercialization prospects of this work, by: 1) Closing essential knowledge gaps required to further develop NR as a neuroprotective pharmaceutical for PD. 2) Establishing our commercial strategy, setting a path for regulatory drug approval, recruiting the right industrial partners, and evaluating opportunities for early commercial revenue, prior to regulatory approval.